<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_source=Chrome&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240313041030&amp;utm_campaign=pubmed-2&amp;v=2.18.0.post9+e462414
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_source=Chrome&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240313041030&amp;utm_campaign=pubmed-2&amp;v=2.18.0.post9+e462414" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Wed, 13 Mar 2024 08:10:32 +0000</lastbuilddate>
<pubDate>Tue, 12 Mar 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Intravenous iron, only for those in need</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38471820/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240313041030&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 13:ehae093. doi: 10.1093/eurheartj/ehae093. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38471820/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240313041030&v=2.18.0.post9+e462414">38471820</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae093>10.1093/eurheartj/ehae093</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38471820</guid>
<pubDate>Tue, 12 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Peter van der Meer</dc:creator>
<dc:creator>Niels Grote Beverborg</dc:creator>
<dc:date>2024-03-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Intravenous iron, only for those in need</dc:title>
<dc:identifier>pmid:38471820</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae093</dc:identifier>
</item>
<item>
<title>Transcatheter Myotomy to Reduce Left Ventricular Outflow Obstruction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38471643/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240313041030&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: With further experience, SESAME may benefit patients requiring septal reduction therapy for obstructive hypertrophic cardiomyopathy, with LVOT obstruction after heart valve replacement, and/or to prepare for transcatheter valve implantation.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Feb 16:S0735-1097(24)00280-8. doi: 10.1016/j.jacc.2024.02.007. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Left ventricular outflow tract (LVOT) obstruction is a source of morbidity in hypertrophic cardiomyopathy (HCM) and a life-threatening complication of transcatheter mitral (TMVR) and aortic valve replacement (TAVR). Available surgical and transcatheter approaches are limited by high surgical risk, unsuitable septal perforators, and heart block requiring permanent pacemakers.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: We report the initial experience of a novel transcatheter electrosurgical procedure developed to mimic surgical myotomy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We used SEptal Scoring Along Midline Endocardium (SESAME) to treat patients, on a compassionate basis, with symptomatic LVOT obstruction or to create space to facilitate TMVR or TAVR.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In this single-center retrospective study between 2021-2023, 76 patients underwent SESAME. Eleven (14%) had classic HCM, and the remainder underwent SESAME to facilitate TMVR or TAVR. All had technically successful SESAME myocardial laceration. Measures to predict post-TMVR LVOT significantly improved (neo-LVOT 42(7,117)to 170(95,265)mm<sup>2</sup>,p&lt;0.001; skirt-neo-LVOT 169(153,193) to 214(180,262)mm<sup>2</sup>,p&lt;0.001). Among patients with HCM, SESAME significantly decreased invasive LVOT gradients (resting: 54[40,70] to 29[12,36]mmHg,p=0.023; provoked 146[100,180] to 85[40,120]mmHg,p=0.076). Seventy-four (97.4%) survived the procedure. Five suffered 3/76(3.9%) iatrogenic ventricular septal defects that did not require repair, and 3/76(3.9%) ventricular free wall perforations. Neither occurred in patients treated for HCM. Permanent pacemakers were required in 4/76(5.3%), including two after concomitant TAVR. Lacerations were stable and did not propagate after SESAME (remaining septum: 5.9±3.3mm to 6.3±3.4mm,p=0.6).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: With further experience, SESAME may benefit patients requiring septal reduction therapy for obstructive hypertrophic cardiomyopathy, with LVOT obstruction after heart valve replacement, and/or to prepare for transcatheter valve implantation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38471643/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240313041030&v=2.18.0.post9+e462414">38471643</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.007>10.1016/j.jacc.2024.02.007</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38471643</guid>
<pubDate>Tue, 12 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Adam B Greenbaum</dc:creator>
<dc:creator>Hiroki A Ueyama</dc:creator>
<dc:creator>Patrick T Gleason</dc:creator>
<dc:creator>Jaffar M Khan</dc:creator>
<dc:creator>Christopher G Bruce</dc:creator>
<dc:creator>Rim N Halaby</dc:creator>
<dc:creator>Toby Rogers</dc:creator>
<dc:creator>George S Hanzel</dc:creator>
<dc:creator>Joe X Xie</dc:creator>
<dc:creator>Isida Byku</dc:creator>
<dc:creator>Robert A Guyton</dc:creator>
<dc:creator>Kendra J Grubb</dc:creator>
<dc:creator>John C Lisko</dc:creator>
<dc:creator>Nikoloz Shekiladze</dc:creator>
<dc:creator>Errol K Inci</dc:creator>
<dc:creator>Elizabeth A Grier</dc:creator>
<dc:creator>Gaetano Paone</dc:creator>
<dc:creator>James M McCabe</dc:creator>
<dc:creator>Robert J Lederman</dc:creator>
<dc:creator>Vasilis C Babaliaros</dc:creator>
<dc:date>2024-03-12</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Transcatheter Myotomy to Reduce Left Ventricular Outflow Obstruction</dc:title>
<dc:identifier>pmid:38471643</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.007</dc:identifier>
</item>
<item>
<title>Metabolic trade-offs constrain the cell size ratio in a nitrogen-fixing symbiosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38471501/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240313041030&amp;v=2.18.0.post9+e462414
      <description>Biological dinitrogen (N(2)) fixation is a key metabolic process exclusively performed by prokaryotes, some of which are symbiotic with eukaryotes. Species of the marine haptophyte algae Braarudosphaera bigelowii harbor the N(2)-fixing endosymbiotic cyanobacteria UCYN-A, which might be evolving organelle-like characteristics. We found that the size ratio between UCYN-A and their hosts is strikingly conserved across sublineages/species, which is consistent with the size relationships of...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Mar 6:S0092-8674(24)00182-X. doi: 10.1016/j.cell.2024.02.016. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Biological dinitrogen (N<sub>2</sub>) fixation is a key metabolic process exclusively performed by prokaryotes, some of which are symbiotic with eukaryotes. Species of the marine haptophyte algae Braarudosphaera bigelowii harbor the N<sub>2</sub>-fixing endosymbiotic cyanobacteria UCYN-A, which might be evolving organelle-like characteristics. We found that the size ratio between UCYN-A and their hosts is strikingly conserved across sublineages/species, which is consistent with the size relationships of organelles in this symbiosis and other species. Metabolic modeling showed that this size relationship maximizes the coordinated growth rate based on trade-offs between resource acquisition and exchange. Our findings show that the size relationships of N<sub>2</sub>-fixing endosymbionts and organelles in unicellular eukaryotes are constrained by predictable metabolic underpinnings and that UCYN-A is, in many regards, functioning like a hypothetical N<sub>2</sub>-fixing organelle (or nitroplast).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38471501/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240313041030&v=2.18.0.post9+e462414">38471501</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.02.016>10.1016/j.cell.2024.02.016</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38471501</guid>
<pubDate>Tue, 12 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Francisco M Cornejo-Castillo</dc:creator>
<dc:creator>Keisuke Inomura</dc:creator>
<dc:creator>Jonathan P Zehr</dc:creator>
<dc:creator>Michael J Follows</dc:creator>
<dc:date>2024-03-12</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Metabolic trade-offs constrain the cell size ratio in a nitrogen-fixing symbiosis</dc:title>
<dc:identifier>pmid:38471501</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.02.016</dc:identifier>
</item>
<item>
<title>The underappreciated diversity of bile acid modifications</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38471500/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240313041030&amp;v=2.18.0.post9+e462414
      <description>The repertoire of modifications to bile acids and related steroidal lipids by host and microbial metabolism remains incompletely characterized. To address this knowledge gap, we created a reusable resource of tandem mass spectrometry (MS/MS) spectra by filtering 1.2 billion publicly available MS/MS spectra for bile-acid-selective ion patterns. Thousands of modifications are distributed throughout animal and human bodies as well as microbial cultures. We employed this MS/MS library to identify...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Mar 6:S0092-8674(24)00185-5. doi: 10.1016/j.cell.2024.02.019. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The repertoire of modifications to bile acids and related steroidal lipids by host and microbial metabolism remains incompletely characterized. To address this knowledge gap, we created a reusable resource of tandem mass spectrometry (MS/MS) spectra by filtering 1.2 billion publicly available MS/MS spectra for bile-acid-selective ion patterns. Thousands of modifications are distributed throughout animal and human bodies as well as microbial cultures. We employed this MS/MS library to identify polyamine bile amidates, prevalent in carnivores. They are present in humans, and their levels alter with a diet change from a Mediterranean to a typical American diet. This work highlights the existence of many more bile acid modifications than previously recognized and the value of leveraging public large-scale untargeted metabolomics data to discover metabolites. The availability of a modification-centric bile acid MS/MS library will inform future studies investigating bile acid roles in health and disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38471500/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240313041030&v=2.18.0.post9+e462414">38471500</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.02.019>10.1016/j.cell.2024.02.019</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38471500</guid>
<pubDate>Tue, 12 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Ipsita Mohanty</dc:creator>
<dc:creator>Helena Mannochio-Russo</dc:creator>
<dc:creator>Joshua V Schweer</dc:creator>
<dc:creator>Yasin El Abiead</dc:creator>
<dc:creator>Wout Bittremieux</dc:creator>
<dc:creator>Shipei Xing</dc:creator>
<dc:creator>Robin Schmid</dc:creator>
<dc:creator>Simone Zuffa</dc:creator>
<dc:creator>Felipe Vasquez</dc:creator>
<dc:creator>Valentina B Muti</dc:creator>
<dc:creator>Jasmine Zemlin</dc:creator>
<dc:creator>Omar E Tovar-Herrera</dc:creator>
<dc:creator>Sarah Moraïs</dc:creator>
<dc:creator>Dhimant Desai</dc:creator>
<dc:creator>Shantu Amin</dc:creator>
<dc:creator>Imhoi Koo</dc:creator>
<dc:creator>Christoph W Turck</dc:creator>
<dc:creator>Itzhak Mizrahi</dc:creator>
<dc:creator>Penny M Kris-Etherton</dc:creator>
<dc:creator>Kristina S Petersen</dc:creator>
<dc:creator>Jennifer A Fleming</dc:creator>
<dc:creator>Tao Huan</dc:creator>
<dc:creator>Andrew D Patterson</dc:creator>
<dc:creator>Dionicio Siegel</dc:creator>
<dc:creator>Lee R Hagey</dc:creator>
<dc:creator>Mingxun Wang</dc:creator>
<dc:creator>Allegra T Aron</dc:creator>
<dc:creator>Pieter C Dorrestein</dc:creator>
<dc:date>2024-03-12</dc:date>
<dc:source>Cell</dc:source>
<dc:title>The underappreciated diversity of bile acid modifications</dc:title>
<dc:identifier>pmid:38471500</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.02.019</dc:identifier>
</item>
<item>
<title>Correction to: Development and Validation of the American Heart Association's PREVENT Equations</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38466792/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240313041030&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 12;149(11):e956. doi: 10.1161/CIR.0000000000001230. Epub 2024 Mar 11.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38466792/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240313041030&v=2.18.0.post9+e462414">38466792</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001230>10.1161/CIR.0000000000001230</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38466792</guid>
<pubDate>Mon, 11 Mar 2024 06:00:00 -0400</pubDate>
<dc:date>2024-03-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: Development and Validation of the American Heart Association's PREVENT Equations</dc:title>
<dc:identifier>pmid:38466792</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001230</dc:identifier>
</item>
<item>
<title>Nature and Magnitude of the Benefits of Dapagliflozin and Empagliflozin for Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38466791/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240313041030&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 12;149(11):839-842. doi: 10.1161/CIRCULATIONAHA.123.068089. Epub 2024 Mar 11.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38466791/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240313041030&v=2.18.0.post9+e462414">38466791</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.068089>10.1161/CIRCULATIONAHA.123.068089</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38466791</guid>
<pubDate>Mon, 11 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>John G F Cleland</dc:creator>
<dc:date>2024-03-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Nature and Magnitude of the Benefits of Dapagliflozin and Empagliflozin for Heart Failure</dc:title>
<dc:identifier>pmid:38466791</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.068089</dc:identifier>
</item>
<item>
<title>Dual (Ischemic and Nonischemic) Cardiomyopathy: A Wolf in Sheep's Clothing</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38466790/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240313041030&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 12;149(11):822-824. doi: 10.1161/CIRCULATIONAHA.123.068090. Epub 2024 Mar 11.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38466790/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240313041030&v=2.18.0.post9+e462414">38466790</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.068090>10.1161/CIRCULATIONAHA.123.068090</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38466790</guid>
<pubDate>Mon, 11 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Gladys Juncà</dc:creator>
<dc:creator>Victoria Delgado</dc:creator>
<dc:date>2024-03-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Dual (Ischemic and Nonischemic) Cardiomyopathy: A Wolf in Sheep's Clothing</dc:title>
<dc:identifier>pmid:38466790</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.068090</dc:identifier>
</item>
<item>
<title>Letter by Heuts et al Regarding Article, "Fractional Flow Reserve-Guided PCI or Coronary Bypass Surgery for 3-Vessel Coronary Artery Disease: 3-Year Follow-Up of the FAME 3 Trial"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38466789/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240313041030&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 12;149(11):892-893. doi: 10.1161/CIRCULATIONAHA.123.066934. Epub 2024 Mar 11.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38466789/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240313041030&v=2.18.0.post9+e462414">38466789</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066934>10.1161/CIRCULATIONAHA.123.066934</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38466789</guid>
<pubDate>Mon, 11 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Samuel Heuts</dc:creator>
<dc:creator>Patrick O Myers</dc:creator>
<dc:creator>Matthias Siepe</dc:creator>
<dc:date>2024-03-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Heuts et al Regarding Article, "Fractional Flow Reserve-Guided PCI or Coronary Bypass Surgery for 3-Vessel Coronary Artery Disease: 3-Year Follow-Up of the FAME 3 Trial"</dc:title>
<dc:identifier>pmid:38466789</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066934</dc:identifier>
</item>
<item>
<title>Antiarrhythmic Drug Therapy: Where Do We Go From Here?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38466788/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240313041030&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 12;149(11):801-803. doi: 10.1161/CIRCULATIONAHA.123.066989. Epub 2024 Mar 11.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38466788/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240313041030&v=2.18.0.post9+e462414">38466788</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066989>10.1161/CIRCULATIONAHA.123.066989</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38466788</guid>
<pubDate>Mon, 11 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Peter R Kowey</dc:creator>
<dc:creator>Gerald V Naccarelli</dc:creator>
<dc:date>2024-03-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Antiarrhythmic Drug Therapy: Where Do We Go From Here?</dc:title>
<dc:identifier>pmid:38466788</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066989</dc:identifier>
</item>
<item>
<title>Are Recommendations That Favor Other Agents Over Angiotensin-Converting Enzyme Inhibitors in Africans With Hypertension Justified?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38466787/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240313041030&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 12;149(11):804-806. doi: 10.1161/CIRCULATIONAHA.123.065887. Epub 2024 Mar 11.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38466787/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240313041030&v=2.18.0.post9+e462414">38466787</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065887>10.1161/CIRCULATIONAHA.123.065887</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38466787</guid>
<pubDate>Mon, 11 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Jonathan G Peter</dc:creator>
<dc:creator>Ntobeko A B Ntusi</dc:creator>
<dc:creator>Mpiko Ntsekhe</dc:creator>
<dc:date>2024-03-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Are Recommendations That Favor Other Agents Over Angiotensin-Converting Enzyme Inhibitors in Africans With Hypertension Justified?</dc:title>
<dc:identifier>pmid:38466787</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065887</dc:identifier>
</item>
<item>
<title>Correction to: 2023 Scientific Sessions Abstract 18987</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38466786/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240313041030&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 12;149(11):e959. doi: 10.1161/CIR.0000000000001228. Epub 2024 Mar 11.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38466786/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240313041030&v=2.18.0.post9+e462414">38466786</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001228>10.1161/CIR.0000000000001228</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38466786</guid>
<pubDate>Mon, 11 Mar 2024 06:00:00 -0400</pubDate>
<dc:date>2024-03-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: 2023 Scientific Sessions Abstract 18987</dc:title>
<dc:identifier>pmid:38466786</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001228</dc:identifier>
</item>
<item>
<title>End-Stage Heart Failure in Cardiac Sarcoidosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38466785/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240313041030&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 12;149(11):885-887. doi: 10.1161/CIRCULATIONAHA.123.066962. Epub 2024 Mar 11.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38466785/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240313041030&v=2.18.0.post9+e462414">38466785</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066962>10.1161/CIRCULATIONAHA.123.066962</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38466785</guid>
<pubDate>Mon, 11 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Diana Velikanova</dc:creator>
<dc:creator>Pauli Pöyhönen</dc:creator>
<dc:creator>Jukka Lehtonen</dc:creator>
<dc:creator>Piia Simonen</dc:creator>
<dc:creator>Valtteri Uusitalo</dc:creator>
<dc:creator>Tapani Vihinen</dc:creator>
<dc:creator>Kari Kaikkonen</dc:creator>
<dc:creator>Petri Haataja</dc:creator>
<dc:creator>Tuomas Kerola</dc:creator>
<dc:creator>Tuomas T Rissanen</dc:creator>
<dc:creator>Ville Vepsäläinen</dc:creator>
<dc:creator>Aleksi Alatalo</dc:creator>
<dc:creator>Päivi Pietilä-Effati</dc:creator>
<dc:creator>Markku Kupari</dc:creator>
<dc:date>2024-03-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>End-Stage Heart Failure in Cardiac Sarcoidosis</dc:title>
<dc:identifier>pmid:38466785</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066962</dc:identifier>
</item>
<item>
<title>Correction to: 2023 Scientific Sessions Abstract 18918</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38466784/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240313041030&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 12;149(11):e958. doi: 10.1161/CIR.0000000000001229. Epub 2024 Mar 11.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38466784/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240313041030&v=2.18.0.post9+e462414">38466784</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001229>10.1161/CIR.0000000000001229</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38466784</guid>
<pubDate>Mon, 11 Mar 2024 06:00:00 -0400</pubDate>
<dc:date>2024-03-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: 2023 Scientific Sessions Abstract 18918</dc:title>
<dc:identifier>pmid:38466784</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001229</dc:identifier>
</item>
<item>
<title>Letter by Rodriguez et al Regarding Article, "Fractional Flow Reserve-Guided PCI or Coronary Bypass Surgery for 3-Vessel Coronary Artery Disease: 3-Year Follow-Up of the FAME 3 Trial"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38466783/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240313041030&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 12;149(11):894-895. doi: 10.1161/CIRCULATIONAHA.123.067446. Epub 2024 Mar 11.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38466783/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240313041030&v=2.18.0.post9+e462414">38466783</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067446>10.1161/CIRCULATIONAHA.123.067446</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38466783</guid>
<pubDate>Mon, 11 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Alfredo E Rodriguez</dc:creator>
<dc:creator>Carlos Fernandez-Pereira</dc:creator>
<dc:creator>Juan Mieres</dc:creator>
<dc:date>2024-03-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Rodriguez et al Regarding Article, "Fractional Flow Reserve-Guided PCI or Coronary Bypass Surgery for 3-Vessel Coronary Artery Disease: 3-Year Follow-Up of the FAME 3 Trial"</dc:title>
<dc:identifier>pmid:38466783</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067446</dc:identifier>
</item>
<item>
<title>Response by Zimmermann et al to Letter Regarding Article, "Fractional Flow Reserve-Guided PCI or Coronary Bypass Surgery for 3-Vessel Coronary Artery Disease: 3-Year Follow-Up of the FAME 3 Trial"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38466782/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240313041030&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 12;149(11):896. doi: 10.1161/CIRCULATIONAHA.123.068238. Epub 2024 Mar 11.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38466782/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240313041030&v=2.18.0.post9+e462414">38466782</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.068238>10.1161/CIRCULATIONAHA.123.068238</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38466782</guid>
<pubDate>Mon, 11 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Frederik M Zimmermann</dc:creator>
<dc:creator>Victoria Y Ding</dc:creator>
<dc:creator>William F Fearon</dc:creator>
<dc:date>2024-03-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Response by Zimmermann et al to Letter Regarding Article, "Fractional Flow Reserve-Guided PCI or Coronary Bypass Surgery for 3-Vessel Coronary Artery Disease: 3-Year Follow-Up of the FAME 3 Trial"</dc:title>
<dc:identifier>pmid:38466782</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.068238</dc:identifier>
</item>
<item>
<title>Correction to: 2023 Scientific Sessions Abstract 18890</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38466781/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240313041030&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 12;149(11):e957. doi: 10.1161/CIR.0000000000001227. Epub 2024 Mar 11.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38466781/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240313041030&v=2.18.0.post9+e462414">38466781</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001227>10.1161/CIR.0000000000001227</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38466781</guid>
<pubDate>Mon, 11 Mar 2024 06:00:00 -0400</pubDate>
<dc:date>2024-03-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: 2023 Scientific Sessions Abstract 18890</dc:title>
<dc:identifier>pmid:38466781</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001227</dc:identifier>
</item>
<item>
<title>Abnormal Progenitor Cell Differentiation and Cardiomyocyte Proliferation in Hypoplastic Right Heart Syndrome</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38466780/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240313041030&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 12;149(11):888-891. doi: 10.1161/CIRCULATIONAHA.123.064213. Epub 2024 Mar 11.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38466780/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240313041030&v=2.18.0.post9+e462414">38466780</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064213>10.1161/CIRCULATIONAHA.123.064213</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38466780</guid>
<pubDate>Mon, 11 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Yang Yu</dc:creator>
<dc:creator>Cankun Wang</dc:creator>
<dc:creator>Shiqiao Ye</dc:creator>
<dc:creator>Zhaohui Xu</dc:creator>
<dc:creator>Hui Lin</dc:creator>
<dc:creator>Karen Texter</dc:creator>
<dc:creator>Vasudha Shukla</dc:creator>
<dc:creator>Samir Ghadiali</dc:creator>
<dc:creator>Qin Ma</dc:creator>
<dc:creator>Vidu Garg</dc:creator>
<dc:creator>Ming-Tao Zhao</dc:creator>
<dc:date>2024-03-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Abnormal Progenitor Cell Differentiation and Cardiomyocyte Proliferation in Hypoplastic Right Heart Syndrome</dc:title>
<dc:identifier>pmid:38466780</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.064213</dc:identifier>
</item>
<item>
<title>2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38466244/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240313041030&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Mar 2:S0735-1097(23)08354-7. doi: 10.1016/j.jacc.2023.12.024. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38466244/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240313041030&v=2.18.0.post9+e462414">38466244</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.12.024>10.1016/j.jacc.2023.12.024</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38466244</guid>
<pubDate>Mon, 11 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Writing Committee</dc:creator>
<dc:creator>Thomas M Maddox</dc:creator>
<dc:creator>James L Januzzi</dc:creator>
<dc:creator>Larry A Allen</dc:creator>
<dc:creator>Khadijah Breathett</dc:creator>
<dc:creator>Sara Brouse</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:creator>Leslie L Davis</dc:creator>
<dc:creator>Gregg C Fonarow</dc:creator>
<dc:creator>Nasrien E Ibrahim</dc:creator>
<dc:creator>JoAnn Lindenfeld</dc:creator>
<dc:creator>Frederick A Masoudi</dc:creator>
<dc:creator>Shweta R Motiwala</dc:creator>
<dc:creator>Estefania Oliveros</dc:creator>
<dc:creator>Mary Norine Walsh</dc:creator>
<dc:creator>Alan Wasserman</dc:creator>
<dc:creator>Clyde W Yancy</dc:creator>
<dc:creator>Quentin R Youmans</dc:creator>
<dc:date>2024-03-11</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee</dc:title>
<dc:identifier>pmid:38466244</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.12.024</dc:identifier>
</item>
<item>
<title>Cardiovascular Management of Patients Undergoing Hematopoietic Stem Cell Transplantation: From Pretransplantation to Survivorship: A Scientific Statement From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38465648/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240313041030&amp;v=2.18.0.post9+e462414
      <description>Hematopoietic stem cell transplantation can cure various disorders but poses cardiovascular risks, especially for elderly patients and those with cardiovascular diseases. Cardiovascular evaluations are crucial in pretransplantation assessments, but guidelines are lacking. This American Heart Association scientific statement summarizes the data on transplantation-related complications and provides guidance for the cardiovascular management throughout transplantation. Hematopoietic stem cell...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 11. doi: 10.1161/CIR.0000000000001220. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Hematopoietic stem cell transplantation can cure various disorders but poses cardiovascular risks, especially for elderly patients and those with cardiovascular diseases. Cardiovascular evaluations are crucial in pretransplantation assessments, but guidelines are lacking. This American Heart Association scientific statement summarizes the data on transplantation-related complications and provides guidance for the cardiovascular management throughout transplantation. Hematopoietic stem cell transplantation consists of 4 phases: pretransplantation workup, conditioning therapy and infusion, immediate posttransplantation period, and long-term survivorship. Complications can occur during each phase, with long-term survivors facing increased risks for late effects such as cardiovascular disease, secondary malignancies, and endocrinopathies. In adults, arrhythmias such as atrial fibrillation and flutter are the most frequent acute cardiovascular complication. Acute heart failure has an incidence ranging from 0.4% to 2.2%. In pediatric patients, left ventricular systolic dysfunction and pericardial effusion are the most common cardiovascular complications. Factors influencing the incidence and risk of complications include pretransplantation therapies, transplantation type (autologous versus allogeneic), conditioning regimen, comorbid conditions, and patient age. The pretransplantation cardiovascular evaluation consists of 4 steps: (1) initial risk stratification, (2) exclusion of high-risk cardiovascular disease, (3) assessment of cardiac reserve, and (4) optimization of cardiovascular reserve. Clinical risk scores could be useful tools for the risk stratification of adult patients. Long-term cardiovascular management of hematopoietic stem cell transplantation survivors includes optimizing risk factors, monitoring, and maintaining a low threshold for evaluating cardiovascular causes of symptoms. Future research should prioritize refining risk stratification and creating evidence-based guidelines and strategies to optimize outcomes in this growing patient population.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38465648/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240313041030&v=2.18.0.post9+e462414">38465648</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001220>10.1161/CIR.0000000000001220</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38465648</guid>
<pubDate>Mon, 11 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Salim S Hayek</dc:creator>
<dc:creator>Vlad G Zaha</dc:creator>
<dc:creator>Carmel Bogle</dc:creator>
<dc:creator>Anita Deswal</dc:creator>
<dc:creator>Amelia Langston</dc:creator>
<dc:creator>Seth Rotz</dc:creator>
<dc:creator>Alexi Vasbinder</dc:creator>
<dc:creator>Eric Yang</dc:creator>
<dc:creator>Tochukwu Okwuosa</dc:creator>
<dc:creator>American Heart Association Cardio-Oncology Committee of the Council on Clinical Cardiology and Council on Genomic and Precision Medicine; and the Council on Cardiovascular and Stroke Nursing</dc:creator>
<dc:date>2024-03-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Cardiovascular Management of Patients Undergoing Hematopoietic Stem Cell Transplantation: From Pretransplantation to Survivorship: A Scientific Statement From the American Heart Association</dc:title>
<dc:identifier>pmid:38465648</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001220</dc:identifier>
</item>
<item>
<title>Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With Left Main Disease With or Without Diabetes: Findings From a Pooled Analysis of 4 Randomized Clinical Trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38465592/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240313041030&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In patients with left main disease considered equally suitable for PCI or CABG and with largely low to intermediate SYNTAX scores, diabetes was associated with higher rates of death and cardiovascular events through 5 years. Compared with CABG, PCI resulted in no difference in the risk of death, a lower risk of early stroke regardless of diabetes status, and a higher risk of spontaneous MI and repeat coronary revascularization, with larger late absolute excess risks in patients with...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 11. doi: 10.1161/CIRCULATIONAHA.123.065571. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Diabetes may be associated with differential outcomes in patients undergoing left main coronary revascularization with percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG). The aim of this study was to investigate outcomes in patients with left main disease with and without diabetes undergoing PCI versus CABG.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Individual patient data were pooled from 4 trials (SYNTAX [TAXUS Drug-Eluting Stent Versus Coronary Artery Bypass Surgery for the Treatment of Narrowed Arteries], PRECOMBAT [Bypass Surgery Versus Angioplasty Using Sirolimus-Eluting Stent in Patients With Left Main Coronary Artery Disease], NOBLE [PCI vs. CABG in the Treatment of Unprotected Left Main Stenosis], and EXCEL [Evaluation of XIENCE Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization]) that randomized patients with left main disease to PCI or CABG. Patients were considered suitable for either approach. Patients were categorized by diabetes status. Kaplan-Meier event rates, Cox model hazard ratios, and interactions were assessed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 4393 patients, 1104 (25.1%) had diabetes. Patients with diabetes experienced higher rates of 5-year death (158/1104 [Kaplan-Meier rate, 14.7%] versus 297/3289 [9.3%]; <i>P</i>&lt;0.001), spontaneous myocardial infarction (MI; 67/1104 [6.7%] versus 114/3289 [3.7%]; <i>P</i>&lt;0.001), and repeat revascularization (189/1104 [18.5%] versus 410/3289 [13.2%]; <i>P</i>&lt;0.001). Rates of all-cause mortality did not differ after PCI versus CABG in those with (84/563 [15.3%] versus 74/541 [14.1%]; hazard ratio, 1.11 [95% CI, 0.82-1.52]) or without (155/1634 [9.7%] versus 142/1655 [8.9%]; hazard ratio, 1.08 [95% CI, 0.86-1.36; <i>P</i><sub>intHR</sub>=0.87) diabetes. Rates of stroke within 1 year were lower with PCI versus CABG in the entire population, with no heterogeneity based on diabetes status (<i>P</i><sub>intHR</sub>=0.51). The 5-year rates of spontaneous MI and repeat coronary revascularization were higher after PCI regardless of diabetes status (spontaneous MI: 45/563 [8.9%] versus 22/541 [4.4%] in diabetes and 82/1634 [5.3%] versus 32/1655 [2.1%] in no diabetes, <i>P</i><sub>intHR</sub>=0.47; repeat revascularization: 127/563 [24.5%] versus 62/541 [12.4%] in diabetes and 254/1634 [16.3%] versus 156/1655 [10.1%] in no diabetes, <i>P</i><sub>intHR</sub>=0.18). For spontaneous MI and repeat revascularization, there were greater absolute excess risks beyond 1 year in patients with diabetes (4.9% and 9.9%) compared with those without (2.1% and 4.3%; <i>P</i><sub>intARD</sub>=0.047 and 0.016).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In patients with left main disease considered equally suitable for PCI or CABG and with largely low to intermediate SYNTAX scores, diabetes was associated with higher rates of death and cardiovascular events through 5 years. Compared with CABG, PCI resulted in no difference in the risk of death, a lower risk of early stroke regardless of diabetes status, and a higher risk of spontaneous MI and repeat coronary revascularization, with larger late absolute excess risks in patients with diabetes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifiers: NCT01205776, NCT0146651, NCT00422968, and NCT00114972.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38465592/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240313041030&v=2.18.0.post9+e462414">38465592</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065571>10.1161/CIRCULATIONAHA.123.065571</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38465592</guid>
<pubDate>Mon, 11 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Prakriti Gaba</dc:creator>
<dc:creator>Joseph F Sabik</dc:creator>
<dc:creator>Sabina A Murphy</dc:creator>
<dc:creator>Andrea Bellavia</dc:creator>
<dc:creator>Patrick T O'Gara</dc:creator>
<dc:creator>Peter K Smith</dc:creator>
<dc:creator>Patrick W Serruys</dc:creator>
<dc:creator>A Pieter Kappetein</dc:creator>
<dc:creator>Seung-Jung Park</dc:creator>
<dc:creator>Duk-Woo Park</dc:creator>
<dc:creator>Evald H Christiansen</dc:creator>
<dc:creator>Niels R Holm</dc:creator>
<dc:creator>Per H Nielsen</dc:creator>
<dc:creator>Marc S Sabatine</dc:creator>
<dc:creator>Gregg W Stone</dc:creator>
<dc:creator>Brian A Bergmark</dc:creator>
<dc:date>2024-03-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With Left Main Disease With or Without Diabetes: Findings From a Pooled Analysis of 4 Randomized Clinical Trials</dc:title>
<dc:identifier>pmid:38465592</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065571</dc:identifier>
</item>
<item>
<title>Exercise therapy for chronic symptomatic peripheral artery disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38461405/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240313041030&amp;v=2.18.0.post9+e462414
      <description>All guidelines worldwide strongly recommend exercise as a pillar of the management of patients affected by lower extremity peripheral artery disease (PAD). Exercise therapy in this setting presents different modalities, and a structured programme provides optimal results. This clinical consensus paper is intended for clinicians to promote and assist for the set-up of comprehensive exercise programmes to best advice in patients with symptomatic chronic PAD. Different exercise training protocols...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 10:ehad734. doi: 10.1093/eurheartj/ehad734. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">All guidelines worldwide strongly recommend exercise as a pillar of the management of patients affected by lower extremity peripheral artery disease (PAD). Exercise therapy in this setting presents different modalities, and a structured programme provides optimal results. This clinical consensus paper is intended for clinicians to promote and assist for the set-up of comprehensive exercise programmes to best advice in patients with symptomatic chronic PAD. Different exercise training protocols specific for patients with PAD are presented. Data on patient assessment and outcome measures are narratively described based on the current best evidence. The document ends by highlighting disparities in access to supervised exercise programmes across Europe and the series of gaps for evidence requiring further research.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38461405/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240313041030&v=2.18.0.post9+e462414">38461405</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad734>10.1093/eurheartj/ehad734</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38461405</guid>
<pubDate>Sun, 10 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Lucia Mazzolai</dc:creator>
<dc:creator>Jill Belch</dc:creator>
<dc:creator>Maarit Venermo</dc:creator>
<dc:creator>Victor Aboyans</dc:creator>
<dc:creator>Marianne Brodmann</dc:creator>
<dc:creator>Alessandra Bura-Rivière</dc:creator>
<dc:creator>Sebastien Debus</dc:creator>
<dc:creator>Christine Espinola-Klein</dc:creator>
<dc:creator>Amy E Harwood</dc:creator>
<dc:creator>John A Hawley</dc:creator>
<dc:creator>Stefano Lanzi</dc:creator>
<dc:creator>Juraj Madarič</dc:creator>
<dc:creator>Guillaume Mahé</dc:creator>
<dc:creator>Davide Malatesta</dc:creator>
<dc:creator>Oliver Schlager</dc:creator>
<dc:creator>Arno Schmidt-Trucksäss</dc:creator>
<dc:creator>Chris Seenan</dc:creator>
<dc:creator>Henrik Sillesen</dc:creator>
<dc:creator>Garry A Tew</dc:creator>
<dc:creator>Adriana Visonà</dc:creator>
<dc:date>2024-03-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Exercise therapy for chronic symptomatic peripheral artery disease</dc:title>
<dc:identifier>pmid:38461405</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad734</dc:identifier>
</item>





























</channel>
</rss>